Cellulitis

This research explores the use of a high-resolution microvessel ultrasound imaging system to observe scarring and monitor wound healing in patients with chronic ulcers. The study aims to see if treatments affect the number of tiny blood vessels and circulation around the wound, focusing on chronic diabetic and venous ulcers. It is an interventional study led by the Mayo Clinic that does not involve drug phases or masking methods. Participants with chronic diabetic and venous ulcers will receive standard wound care including wound debridement and treatment. During the study, they will undergo research-specific microvessel ultrasound examinations to assess microvessel formation and tissue stiffness near the ulcer and in unaffected skin. Additionally, two skin biopsies will be taken to gather more information about the wound and skin tissue. Participants will be evaluated over a period of three months, during which microvessel imaging is the primary outcome being measured. The study includes monitoring wound healing progress through ultrasound and skin biopsy data. Patients will be assessed for blood glucose control, blood supply to the wound, and other clinical indicators to understand the healing process. Safety and wound status will be regularly checked throughout the study duration.

Carpal Tunnel Syndrome is a common condition that causes symptoms like tingling, pain, numbness, and weakness. Surgery called carpal tunnel release is the most effective treatment. This research compares two types of sutures used to close wounds after surgery — absorbable and non-absorbable — to see if one type affects the chance of wound infection. The study is a randomized controlled trial investigating how sutures influence infections after surgery. Participants will receive carpal tunnel release surgery where the flexor retinaculum is cut to relieve pressure. After surgery, wounds will be closed using either absorbable sutures (Vicryl rapide or Safil quick) or non-absorbable sutures (Ethilon or Flexocrin). Both suture types are commonly used, but this study aims to find if one leads to fewer infections. The trial does not use masking, and participants are randomly assigned to one of the two suture groups. During the study, researchers will assess wound healing using the ASEPSIS wound score between 10 and 14 days after surgery. Patients will also record their pain using a Numeric Rating Scale for up to three weeks after surgery. Use of antibiotics, hand therapy, and any extra doctor visits will be recorded. The study is sponsored by Gelre Hospitals and includes adult participants aged 18 and older. Participation may last several weeks for follow-up and assessments.

Researchers are conducting a study called Acutelines, a large data and biobank project at the University Medical Center Groningen in the Netherlands. It focuses on patients with a wide range of acute medical conditions who present to the Emergency Department. The goal is to improve how acute diseases are recognized and treated, understand their outcomes, and support personalized medicine by collecting detailed clinical data, imaging, and biomaterials over time. Participants have their medical information, including demographics, health status, medical history, vital signs, diagnostic tests, and treatments, systematically collected. Biomaterials such as blood, urine, feces, and hair are gathered from patients who meet certain severity criteria. Data collection occurs during hospital admission, including continuous monitoring, and continues with follow-ups at 3 months, 1 year, 2 years, and 5 years after the initial emergency visit. Throughout the study, various assessments are performed, such as quality of life, physical functioning, mental health, symptoms, and hospital length of stay. Researchers collect data on mortality and other health outcomes for up to 50 years. The study uses digital tools to automate data capture and integrates information from multiple healthcare sources. Participants will be monitored closely during hospitalization and at scheduled intervals afterward to help improve understanding and treatment of acute diseases.

Researchers are evaluating the effect of adding clindamycin to the usual treatment of skin and soft tissue infections caused by Staphylococcus aureus in patients from Sierra Leone. The study aims to see if this combination leads to faster healing and fewer infection recurrences. These infections can be severe due to toxins produced by the bacteria, and clindamycin is believed to reduce these toxins. The trial compares standard treatment, usually involving anti-staphylococcal penicillin with or without surgery to drain infection, to the same treatment plus clindamycin. Clindamycin is given either orally or intravenously for 7 days, with dosing adjusted by weight. Participants receive either the standard care alone or the standard care plus clindamycin, and the study is open-label, meaning both patients and doctors know which treatment is given. Participants will be adults with confirmed Staphylococcus aureus skin infections who require systemic therapy. They will be monitored for clinical cure at 7 and 14 days, changes in inflammation, symptom resolution time, possible side effects, microbiological failure, and infections returning over 6 months. Follow-up visits may occur during hospital admission or at home, and safety and treatment outcomes will be carefully tracked throughout the study period.

Necrotizing soft-tissue infection (NSTI) is a rare and severe bacterial infection that progresses rapidly within soft tissues, with a high mortality rate that has not improved in recent decades. Researchers are studying the effect of adding hyperbaric oxygen (HBO2) treatment to the standard care, which includes surgery, intensive care, and broad-spectrum antibiotics, to see if it can reduce death rates within 30 days of treatment. Participants will be randomly assigned to receive either the standard care alone or standard care plus HBO2 treatment. HBO2 sessions involve breathing 100% oxygen at high pressure for 60 to 90 minutes, starting as soon as possible and within 12 hours after randomization. At least three HBO2 sessions will be given within 48 hours, with up to five sessions allowed within 96 hours if the patient remains unstable. During the study, researchers will monitor survival rates at 30 and 90 days, and track amputations within 7 days after treatment. Participants will receive intensive medical care including surgery and antibiotics, and the study will assess how the addition of HBO2 influences outcomes. The trial will continue until June 2033, and participants will be carefully observed throughout the treatment and follow-up periods.

This research investigates the effects of an Aescin-based herbal extract called Reparil compared with Ibuprofen in managing symptoms after surgical removal of impacted lower wisdom teeth. The study focuses on people aged 18 to 40 who undergo this common oral surgery, aiming to find out if the herbal treatment offers pain relief and reduces swelling and limited mouth opening with fewer side effects than traditional nonsteroidal anti-inflammatory drugs (NSAIDs). Participants will be randomly assigned to receive either Reparil tablets containing 20 mg Aescin or 400 mg Ibuprofen tablets, each taken orally three times a day for five days after surgery. Both groups follow the same schedule, and a rescue pain medication is available if needed. Assessments will occur before surgery and on days 2 and 7 afterward to measure pain, facial swelling using 3D scanning, and mouth opening using a digital caliper. During the study, participants will have their pain levels, facial swelling, and jaw movement tracked at specific intervals. Researchers will record any adverse effects and analyze data to compare the treatments' impacts. The total involvement includes the surgery and follow-up visits on days 2 and 7, helping to evaluate the herbal extract as a potential alternative to Ibuprofen for managing post-surgical symptoms.

Researchers are evaluating whether a shorter 5-day course of oral flucloxacillin is not worse than the standard 7-day course for treating cellulitis of the leg in adults seen in primary care. Cellulitis is a painful skin and tissue infection often accompanied by swelling, redness, and systemic symptoms like fever and fatigue. This study aims to compare pain levels during days 6-14 after starting treatment, which reflects ongoing or recurring symptoms important to patients. Participants are randomly assigned to one of two groups: one receives flucloxacillin 500mg four times daily for 5 days followed by placebo for 2 days, while the other receives flucloxacillin 500mg four times daily for the full 7 days, with the last 2 days blinded. This quadruple-blind study involves usual care plus the assigned treatment course, and it will also assess the cost implications of the shorter treatment from NHS and personal perspectives. During the trial, participants will complete daily questionnaires about their symptoms and experiences. Researchers will measure pain from days 7 to 16, quality of life, leg swelling and warmth, recovery time, hospital admissions, and recurrence of cellulitis over 12 months. Safety and complications will be monitored throughout. The total study duration extends up to 12 months for follow-up.

Researchers are evaluating the effectiveness of multiple human placental membrane products, called CAMPs, combined with Standard of Care (SOC) versus SOC alone in treating nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). This multicenter, prospective, randomized controlled trial uses a modified platform design to compare different CAMP products, including AM/Single and AM/Double, in promoting ulcer closure over 12 weeks. Participants will receive weekly treatments depending on their assigned group. The Standard of Care involves cleaning, debridement, moisture balance, and offloading or compression as appropriate. Those in CAMP groups will receive weekly applications of either AM/Single (a single layer human amniotic membrane allograft) or AM/Double (a double layer allograft) in addition to Standard of Care. Treatment continues until the ulcer closes or up to 12 weeks. During the study, participants will attend weekly visits for treatment and evaluation. Researchers will assess ulcer closure rates, time to closure, percent area reduction, pain changes, adverse events, and quality of life improvements over 12 weeks. The study monitors participants closely to measure healing progress and safety of the treatments throughout the trial duration.

Researchers are evaluating two different techniques for closing the midline laparotomy incision in emergency colorectal surgery to prevent incisional hernias. This study aims to provide evidence on the incidence of incisional hernia and related complications, addressing the lack of consensus in current guidelines and the limited quality of existing research. The study compares closure using the "small bites" technique alone with closure using the same technique plus a partially absorbable polypropylene mesh placed suprapubically. The "small bites" technique involves a specific method of suturing with a monofilament polydioxanone suture. When mesh is used, it is fixed with absorbable staples and sometimes sutures, and drainage is applied based on surgical discretion. Participants will undergo emergency colorectal surgery with either closure method randomly assigned. Researchers will monitor for incisional hernia occurrence one year after surgery and assess wound infections within 30 days and morbidity and mortality within 90 days post-operation. The study involves follow-up visits to evaluate these outcomes and ensure participant safety throughout the trial duration.

Researchers are evaluating the use of two different mesh materials, polypropylene (PP) and polyvinylidene fluoride (PVDF), for closing midline laparotomy incisions in emergency colorectal surgery. This study focuses on high-risk patients for incisional hernia and aims to provide evidence on differences in surgical wound infection rates and related complications like chronic pain. There are currently no specific guidelines comparing these mesh types in this surgical context. Participants undergoing emergency colorectal surgery will have their midline laparotomy closed using a "small bites" technique combined with either a prophylactic suprafascial PVDF mesh or a PP mesh. Randomization occurs at the time of laparotomy closure to assign patients to one of these two groups. Surgeries are performed according to each patient's pathology. During the study, researchers will monitor surgical wound infection incidence for 30 days after surgery. They will also track rates of incisional hernia at one year and morbidity and mortality within 90 days postoperatively. Participants will be followed through these periods to assess outcomes and any complications related to the mesh materials used.